We wish to extend a hearty congratulations to our sponsor ALung Technologies!
As we discovered via Medcity News, and as originally reported by Trib Live, ALung recently raised $12 million to support the U.S. regulatory approval process for the Hemolung RAS, the world’s first fully integrated respiratory dialysis system.
ALung selected T3 Labs as its preclinical CRO for the Hemolung RAS, benefitting from our collective expertise and experience.
Earlier this year Jeremy Kimmel, PhD and ALung’s director of new technology shared, “I am convinced this recommendation [to shift preclinical models] has accelerated our product refinement testing and preclinical trials, saving ALung time and money at every step along the way. Through smart trial and error, we have gone from inconsistent initial outcomes to a position of confidence that we have determined the best protocol to use.”
You can read the entire ALung preclinical case study with T3 Labs here.
To find out how T3 Labs can maximize your investment in preclinical research, contact email@example.com or call (404) 252-0600.